FBXO11 and breast carcinoma: It is a direct functional target of miR-621 in breast cancer, and high miR-621 levels enhance the sensitivity of breast cancer cells to paclitaxel and carboplatin by suppressing FBXO11 and enhancing p53 activity [14].